EGFR and colorectal cancer: Treatment switching was included in the protocol for Study 20020408 based on prior evidence of the activity of panitumumab and cetuximab, a similar anti-EGFR (epidermal growth factor receptor) monoclonal antibody, in colorectal cancer [13].